TB 500

Product Overview

TB-500 5 mg by Axiolabs is supplied as a vial labeled with 5 mg of Thymosin Beta-4/TB-500-related peptide. TB-500 belongs to the investigational thymosin-related peptide category and is primarily discussed in connection with tissue remodeling, cell migration, wound-healing biology, connective-tissue research, and sports-recovery applications.

A clinically important distinction exists between full-length Thymosin Beta-4 (Tβ4) and TB-500. FDA's Global Substance Registration System identifies TB-500 as the N-terminal acetylated 17–23 fragment of thymosin beta-4, with the seven-amino-acid sequence N-acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln. Full-length human thymosin beta-4 is a separate peptide substance.

This distinction matters because clinical or preclinical findings involving complete thymosin beta-4 should not automatically be attributed to the shorter TB-500 fragment. Commercial peptide labeling sometimes uses the terms "TB-500" and "Thymosin Beta-4" interchangeably even though FDA recognizes them as different substance identities.

As of 2026, TB-500 is not an FDA-approved treatment for tendon injuries, ligament injuries, muscle tears, wound healing, bodybuilding, or athletic recovery. FDA states that it has not identified human exposure data for drug products containing the TB-500 fragment and lacks sufficient information to determine its human safety.

FDA's July 2026 Pharmacy Compounding Advisory Committee materials also proposed that both TB-500 free base and TB-500 acetate not be included on the Section 503A Bulks List after evaluating proposed wound-healing use.

The 5 mg designation therefore describes the stated content of the Axiolabs vial. It should not be interpreted as an approved injection dose, weekly dose, loading dose, or treatment course.

Product Class

• Investigational thymosin-related peptide
• Thymosin beta-4-derived peptide fragment
• Actin-associated research compound
• Experimental tissue-remodeling peptide
• Regenerative medicine research compound
• Wound-healing research peptide
• Non-androgenic compound
• Non-SARM compound
• Non-growth-hormone secretagogue

Indications

Clinical and Research Context

The thymosin beta-4 system has been investigated because of its relationship with actin regulation, cellular migration, tissue remodeling, angiogenesis, inflammatory signaling, and wound repair. These mechanisms have generated interest across regenerative-medicine research.

Research areas associated with thymosin beta-4 biology include:

• Wound repair
• Epithelial regeneration
• Cell migration
• Actin regulation
• Fibroblast activity
• Angiogenic signaling
• Inflammatory modulation
• Connective-tissue remodeling
• Cardiovascular tissue research

However, evidence involving full-length thymosin beta-4 does not establish equivalent therapeutic activity for TB-500. FDA's current safety review specifically states that no human exposure data for TB-500 drug products were identified.

Performance and Recovery Context

Within bodybuilding, athletic, and peptide-research communities, TB-500 is commonly discussed for proposed applications such as:

• Tendon recovery
• Ligament recovery
• Muscle-injury recovery
• Connective-tissue support
• Improved mobility following injury
• Wound-healing support
• Recovery between demanding training sessions

These are not approved therapeutic uses. Controlled human trials have not established that injected TB-500 reliably accelerates recovery from tendon, ligament, or skeletal-muscle injuries.

TB-500 is also not a direct anabolic-androgenic agent. It does not act like Testosterone, Oxandrolone, Nandrolone, Trenbolone, or SARMs through primary androgen-receptor activation.

Potential Benefits

Potential benefits attributed to TB-500 originate largely from biological research on thymosin beta-4 pathways and preclinical regenerative models rather than robust controlled clinical trials of TB-500 itself.

Areas of research interest include:

• Cellular migration during repair
• Actin-dependent tissue remodeling
• Wound-healing pathways
• Connective-tissue biology
• Angiogenesis-related signaling
• Inflammatory-response modulation
• Soft-tissue regeneration research

Such mechanisms make thymosin-related peptides scientifically interesting for injury and regenerative research. They do not, however, prove that commercially supplied TB-500 produces clinically meaningful tendon or ligament healing in humans.

Claims that TB-500 rapidly repairs torn tendons, regenerates damaged ligaments, eliminates injury recovery time, substantially increases flexibility, or directly builds muscle remain insufficiently supported by human evidence.

FDA has additionally highlighted potential safety concerns relating to peptide aggregation, peptide-related impurities, active-ingredient characterization, and immunogenicity.

Synergy & Stacking

TB-500 is frequently discussed alongside other regenerative peptides, growth-factor-related compounds, or endocrine agents. These combinations should be understood as experimental rather than established clinical protocols.

• BPC-157: An investigational 15-amino-acid peptide commonly discussed for gastrointestinal and soft-tissue repair research.
• GHK-Cu: A copper-binding tripeptide associated with extracellular-matrix, skin, fibroblast, and wound-remodeling research.
• Growth Hormone: An endocrine hormone acting through the GH receptor and downstream IGF-1 pathway rather than thymosin signaling.
• Ipamorelin: A ghrelin/GHS-R1a receptor agonist that promotes endogenous GH secretion.
• CJC-1295: An investigational GHRH analogue acting through pituitary growth-hormone signaling.
• Tesamorelin: A GHRH analogue with an established therapeutic role in specific approved formulations for HIV-associated lipodystrophy.

The TB-500 plus BPC-157 combination is particularly common in online regenerative-peptide discussions. However, there is no validated controlled human protocol demonstrating that combining these peptides provides superior tendon, ligament, muscle, or wound healing.

Combining several investigational peptides can also increase uncertainty regarding adverse reactions, product purity, sterility, immunogenicity, and causality if an adverse event occurs.

HRT/TRT Application

TB-500 has no established role in Testosterone Replacement Therapy or conventional Hormone Replacement Therapy.

TB-500 does not:

• Supply Testosterone
• Serve as a testosterone ester
• Primarily activate androgen receptors
• Replace androgen deficiency
• Function as a SERM
• Function as an aromatase inhibitor
• Directly stimulate LH or FSH
• Replace growth hormone

TB-500 is therefore pharmacologically distinct from Testosterone Enanthate, Testosterone Cypionate, Sustanon, or other established androgen-replacement agents.

Because TB-500 is not an androgen-receptor agonist, conventional steroid-mediated suppression of the hypothalamic-pituitary-gonadal axis is not expected to be its primary mechanism. However, absence of androgenic suppression should not be interpreted as evidence of overall systemic safety.

Dosing and Use

Axiolabs TB-500 is labeled as containing 5 mg per vial. This number describes stated vial content only.

There is currently no FDA-approved human TB-500 dosing regimen for:

• Tendon injuries
• Ligament injuries
• Muscle tears
• Wound healing
• Athletic recovery
• Bodybuilding
• General regenerative therapy

The 5 mg vial should therefore not automatically be interpreted as:

• A single administration
• A weekly dose
• A loading dose
• A maintenance dose
• A complete course
• A validated injury-recovery protocol

FDA's 2026 assessment states that human exposure information for TB-500 is lacking, making it impossible to establish a conventional evidence-based therapeutic dosage from current human safety and efficacy data.

Clinical research involving full-length thymosin beta-4 should likewise not be converted directly into dosing instructions for TB-500 because FDA recognizes these as distinct substances.

With any independently manufactured injectable peptide, additional pharmaceutical-quality considerations include:

• Correct molecular identity
• Peptide purity
• Related peptide impurities
• Aggregation
• Sterility
• Bacterial endotoxin
• Particulate contamination
• Concentration accuracy
• Stability during storage

Female Use

TB-500 is non-androgenic and does not primarily activate androgen receptors. Therefore, the classical virilizing effects associated with anabolic-androgenic steroids are not expected from its proposed mechanism.

Effects such as:

• Voice deepening
• Clitoral enlargement
• Male-pattern facial-hair growth
• Androgen-related menstrual effects
• Androgenic scalp-hair loss

are not expected as direct pharmacological consequences of thymosin-related signaling.

However, the absence of androgenicity does not demonstrate safety in women. FDA states that important human safety information for TB-500 is lacking. Reproductive, pregnancy, fetal-development, and breastfeeding safety are not established.

The 5 mg vial strength is not a validated female dose.

Comparative Analysis

TB-500 vs Full-Length Thymosin Beta-4

• TB-500: FDA identifies it as the acetylated 17–23 fragment of thymosin beta-4.
• Thymosin Beta-4: Full-length naturally occurring 43-amino-acid peptide.
• Both are sequence related but are not identical molecular entities.
• Evidence obtained with complete Tβ4 should not automatically be attributed to TB-500.

TB-500 vs BPC-157

• TB-500: Thymosin-derived fragment associated principally with actin and cellular-migration biology.
• BPC-157: Synthetic pentadecapeptide investigated predominantly in preclinical gastrointestinal and tissue-repair models.
• Both are commonly marketed for recovery despite substantial gaps in controlled human evidence.

TB-500 vs GHK-Cu

• TB-500: Thymosin-related peptide associated with actin-dependent cellular processes.
• GHK-Cu: Copper-binding tripeptide associated with extracellular-matrix remodeling, fibroblast biology, and skin research.
• Neither compound is an anabolic steroid or SARM.

TB-500 vs Tesamorelin

• TB-500: Experimental thymosin-derived regenerative peptide.
• Tesamorelin: GHRH analogue that stimulates endogenous GH and has an approved medical indication in specific pharmaceutical formulations.
• Tesamorelin acts through the GH/IGF-1 axis; TB-500 does not.

TB-500 vs Growth Hormone

• TB-500: Investigational thymosin-derived peptide associated with actin and tissue-remodeling pathways.
• Growth Hormone: Endocrine hormone signaling through the GH receptor and downstream IGF-1.
• Approved recombinant GH has recognized medical indications, while TB-500 has no comparable approved therapeutic indication.

TB-500 vs Anabolic Steroids

Anabolic-androgenic steroids produce their characteristic effects primarily through androgen-receptor activation. TB-500 does not share this primary mechanism. Its performance-related interest instead centers on proposed tissue-repair and regenerative effects.

Conclusion

TB-500 5 mg by Axiolabs is supplied as a vial labeled with 5 mg of Thymosin Beta-4/TB-500-related peptide. TB-500 belongs to an investigational class of thymosin-derived compounds associated with actin regulation, cellular migration, tissue remodeling, and wound-healing research.

A central pharmacological consideration is that TB-500 and full-length Thymosin Beta-4 should not be treated as identical molecules. FDA recognizes TB-500 as the acetylated 17–23 fragment of thymosin beta-4, while full-length Tβ4 is registered separately.

TB-500 is not an anabolic steroid, SARM, TRT product, or growth-hormone secretagogue. Claims concerning accelerated tendon, ligament, muscle, or wound healing remain unconfirmed in adequate controlled human trials. The stated 5 mg therefore represents vial content rather than an approved medical or athletic-recovery dose.